Skip to main content
PMC home page
Acta Pharmacologica Sinica logoLink to Acta Pharmacologica Sinica
. 2011 Apr 18;32(5):647–654. doi: 10.1038/aps.2011.2

Sulfated polymannuroguluronate inhibits Tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad

Yan-lin Wu 1,#, Jing Ai 2,#, Jing-ming Zhao 3, Bing Xiong 4, Xiao-jie Xin 2, Mei-yu Geng 2, Xian-liang Xin 2,*, Han-dong Jiang 3,*
PMCID: PMC4002517  PMID: 21499289

Abstract

Aim:

Sulfated polymannuroguluronate (SPMG), a candidate anti-AIDS drug, inhibited HIV replication and interfered with HIV entry into host T lymphocytes. SPMG has high binding affinity for the transactivating factor of the HIV-1 virus (Tat) via its basic domain. However, deletion or substitution of the basic domain affected, but did not completely eliminated Tat-SPMG interactions. Here, we sought to identify other SPMG binding sites in addition to the basic domain.

Methods:

The potential SPMG binding sites were determined using molecular simulation and a surface plasmon resonance (SPR) based competitive inhibition assay. The effect of SPMG on Tat induced adhesion was evaluated using a cell adhesion assay.

Results:

The KKR domain, a novel high-affinity heparin binding site, was identified, which consisted of a triad of Lys12, Lys41, and Arg78. The KKR domain, spatially enclosed SPMG binding site on Tat, functions as another binding domain for SPMG. Further functional evaluation demonstrated that SPMG inhibits Tat-mediated SLK cell adhesion by directly binding to the KKR region.

Conclusion:

The KKR domain is a novel high-affinity binding domain for SPMG. Our findings provide important new insights into the molecular mechanisms of SPMG and a potential therapeutic intervention for Tat-induced cell adhesion.

Keywords: sulfated polymannuroguluronate, transactivating factor of the HIV-1 virus (Tat), binding site, Kaposi's sarcoma, heparin, mutation, HIV-1

Introduction

Kaposi's sarcoma (KS) is the most common tumor in human immunodeficiency virus (HIV)-infected patients and is a leading cause of mortality and morbidity in acquired immune deficiency syndrome (AIDS)1, 2, 3. KS is much more frequent and aggressive in the setting of HIV-1 infection, suggesting that HIV itself, or molecules produced during HIV infection, might play important roles in KS development and progression4. The transactivating factor of the HIV-1 virus (Tat), a polypeptide of 86–102 amino acids released from HIV-1 infected cells, contributes directly to KS pathogenesis5. In addition to the transactivation of HIV-1 gene expression, Tat can promote KS cell adhesion through binding to integrins6, 7. Therefore, the inhibition of Tat activity could be a useful way to inhibit the development and progression of KS in AIDS patients.

Tat-driven activities depend precisely on its interaction with cell surface heparan sulfate (HS) and heparin through their negatively charged sulfate groups8. Conversely, free heparin inhibits the uptake of intracellular Tat and affects the cell surface interaction mediated by Tat9, 10, 11. The basic domain constituted by a stretch of repeated Arg and Lys residues has long been recognized as the sole contributor to this interaction, which is mediated by its heparin binding properties9, 11, 12, 13. However, our previous studies have challenged this notion by identifying a novel heparin-binding KKR domain (Lys12, Lys41, and Arg78) that helps facilitate Tat-driven β1 integrin activation and subsequent adhesion in a heparan sulfate proteoglycan (HSPG)-dependent manner14. These important insights into the binding profile between heparin and Tat will provide a more precise understanding of the comprehensive roles of Tat and aid in the design of new therapeutic agents. Moreover, growing evidence shows that heparin and many heparin analogs represent potent extracellular Tat antagonists of possible therapeutic value10, 15.

Sulfated polymannuroguluronate (SPMG), a new heparin-like sulfated polysaccharide extracted from brown algae, is rich in 1,4-linked β-D-mannuronate, with an average of 1.5 sulfates and 1.0 carboxyl groups per sugar residue and an average molecular weight of 10 kDa. SPMG has entered Phase II clinical trials in China, making it the first marine sulfated polysaccharide with the potential to be approved as an anti-AIDS drug. Our previous in vitro and in vivo studies demonstrated that SPMG inhibited HIV replication and interfered with HIV entry into host T lymphocytes. We further demonstrated that Tat exhibited a high binding affinity for SPMG via its basic domain, thereby inhibiting Tat-induced AIDS-KS16, 17. We also found that substitution of the basic domain affected, but failed to completely eliminate, Tat-SPMG interactions. These results led us to hypothesize that there might exist other SPMG binding sites in addition to the basic domain. In this article, using molecular simulation combined with a surface plasmon resonance (SPR)-based competitive inhibition assay, we found that the KKR domain, a newly identified high-affinity heparin binding site14, functioned as another binding domain for SPMG. Further functional evaluation demonstrated that SPMG inhibited Tat-mediated SLK cell adhesion by directly binding to the KKR region.

Materials and methods

Materials

SPMG, depolymerized by acidic hydrolysis, and then sulfatation (Mw about 8000 Da), was provided by the Marine Drug and Food Institute (Ocean University of China, Qingdao, China). Heparin, HS, chondroitin sulfates A (CSA) and C (CSC), and hyaluronic acid (HA) were obtained from Sigma (St Louis, MO, USA). Anti-GST antibody (sc-459) was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).

Cell culture

SLK cells (derived from an endothelial-origin Kaposi's sarcoma) were kindly provided by the NIH AIDS Research Division. The cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS, Gibco Gaithersburg, MD, USA), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified incubator with 5% CO2.

Computational docking modeling

The amino acid sequence of human T-lymphotropic virus 3 (Tat-III protein) was retrieved from the appropriate NCBI protein database (GI: 328765) and used to search for homologs in the Protein Data Bank (http://www.rcsb.org). Through a BLASTP search, it was found that the NMR structure of Tat-I (PDB entry: 1JFW) was the most homologous protein (83/86 aa, 96% identity)18. Therefore, the structure of Tat-I was used as the template to create a 3D model of Tat-III using the MODELLER program19. Ten models were generated, and these 3D structures were optimized with a conjugate gradient minimization scheme followed by a restrained annealing molecular dynamics simulation. The model with the lowest value for the objective function was selected as the most representative Tat-III model for further study.

Structure-based analysis of our homology model of Tat-III was performed to search for SPMG binding sites using the newly developed AutoDock Vina program20. This program is two orders of magnitude faster than AutoDock4 and enabled us to search for binding sites over the whole surface of Tat-III. Additionally, it is based on the fast iterated local search global optimization of protein-ligand interactions, so the search time increases linearly with atom number. The input PDBQT files of Tat-III and three ligands (2-, 4-, and 8-SPMG) were prepared with AutoDockTools, and the docking operation algorithm was performed in a consistent manner. A large box encompassing the entire Tat-III structure, with dimensions 48 Å×48 Å×42 Å, was generated to take all possible SPMG binding sites into account. Then, the Vina program was applied to account for protein-ligand interactions using a newly developed scoring function that includes the terms gauss type steric interaction, repulsion interaction, hydrogen bond, and torsional free energy. Through large scale validation, the Vina program can significantly improve the accuracy of binding mode predictions20. Finally, the evaluation with the lowest binding energy was used to analyze ligand pose, and the interaction model of SPMG/Tat-III was illustrated with the program Pymol based on the docked complex structure21.

Preparation of Tat and its mutants

Plasmid pGEX-2T (Amersham Pharmacia, Uppsala, Sweden) and pGST-Tat were kindly provided by Prof M GIACCA and M PRESTAI (International Centre for Genetic Engineering and Biotechnology, Trieste, Italy). Tat mutants were constructed using site-directed mutagenesis, yielding a series of GST-Tat mutants (Table 1).

Table 1. Summary of mutated amino acids in the set of GST-Tat mutants.

Mutant name Amino acids change
GST-Tat(G48-R57)A Amino acids 48–57 (basic domain) → Ala
GST-TatK(12,41)A/R78A Lys12, Lys41, Arg78 → Ala
GST-TatK12A Lys12 → Ala
GST-TatK41A Lys41 → Ala
GST-TatR78A Arg78 → Ala
GST-TatK(12,41)A Lys12, Lys41 → Ala
GST-TatK12A/R78A Lys12, Arg78 → Ala
GST-TatK41A/R78A Lys41, Arg78 → Ala
GST-Tat(G48-R57)A/K(12,41)A/R78A Amino acids 48–57, Lys12, Lys41, Arg78 → Ala
Open in a new tab

Recombinant wild type HIV-1 Tat and the different Tat mutants were expressed in Escherichia coli as glutathione S-transferase (GST) fusion proteins and purified to homogeneity from bacterial lysates by glutathione-sepharose affinity chromatography (Amersham Pharmacia) as described previously14. The purity and integrity of the protein product were routinely checked by SDS-polyacrylamide gel electrophoresis and 0.25% Coomassie brilliant blue R-250 staining. The identification of mutant products was further carried out by MS-MS spectral analysis. In addition, the similarity of the secondary structure of the mutated products to the native Tat protein was predicted using a position-specific scoring method14. The purified proteins were stored in aliquots at -80 °C until use9.

Surface plasmon resonance assay

To characterize Tat binding with SPMG, kinetic properties and competitive inhibition were examined using a surface plasmon resonance assay (SPR, BIAcore X, Uppsala, Sweden). For this purpose, SPMG was immobilized to a CM5 sensor chip according to the established method22, 23. The immobilization procedure was carried out at 25 °C and at a constant flow rate of 5 μL/min in HBS-EP [0.01 mol/L HEPES, pH 7.4, 0.15 mol/L NaCl, 3 mmol/L EDTA, and 0.005% polysorbate 20 (v/v)]. To assess the real-time binding capacity, 50 μL of GST-Tat or the relevant mutant was injected over the sensor chip surface with the immobilized SPMG, followed by 5 min of washing with HBS-EP buffer. The sensor chip surface was regenerated using 2 mol/L NaCl. All binding experiments were performed at 25 °C with a constant flow rate of 15 μL/min HBS-EP. To correct for nonspecific binding and bulk refractive index change, a blank channel (FC2) without SPMG was employed as a control for each experiment. Sensorgrams for all binding interactions were recorded in real time and analyzed after subtraction of channel blanks. Changes in mass due to the binding response were recorded as resonance units (RU). Binding kinetics and affinities were calculated using BIAcore software 3.1. Competitive inhibition experiments were conducted with the same protocol, except that a 50 μL mixture of GST-Tat or the relevant mutant and inhibitors that had been preincubated for 3 min at 37 °C was used.

Cell adhesion assay

To guarantee that plates were coated with the same amount of each tested protein, anti-GST antibody was adsorbed to polystyrene microplates (Costar, Cambridge, MA, USA) by overnight incubation at 4 °C in 100 mmol/L carbonate buffer (pH 9.6) at a concentration of 10 μg/mL. The plates were subsequently washed three times with Tris-buffered saline+Tween 20 (TBS-T) and then filled with 1.25% BSA-PBS and incubated for 2 h at 37 °C. After three washes with TBS-T, 40 μg/mL of GST alone, GST-Tat or the relevant mutant Tat protein was added to the wells and incubated for 1 h at 37 °C. The plate was next washed three times with PBS-T. Then, 100 μL of SLK cell suspension was added to each well (3×105 cells/mL in RPMI-1640 with 10 % FCS). After incubation for 1 h at 37 °C in a 5% CO2 atmosphere, non-adherent cells were removed by careful aspiration and three washes with RPMI 1640. Adherent cells were fixed, stained, and quantified as previously described24. A SPMG competition cell adhesion assay was conducted with the same procedure, except that SPMG at defined concentrations was added to each well. Each experiment was performed in triplicate and replicated three times.

Statistical analysis

Data were presented as means±SD, and differences were considered significant when P<0.05 as determined by Student's t-tests.

Results

Lys12, Lys41, and Arg78 triad is predicted as a novel SPMG binding site

Computational modeling was first employed with the aim of identifying potential SPMG binding sites. The homology model of Tat protein (Tat-III) constructed on the basis of NMR data was used as the target structure, and several SPMG oligosaccharides including di-, tetra-, and octa-saccharides were selected as docking probes. In the disaccharide SPMG model, SPMG was noted to preferentially interact with a triad of basic residues (Lys12, Lys41, and Arg78 (KKR); Figure 1A–1C, highlighted in yellow in Figure 1C).

Figure 1.

Figure 1

Open in a new tab

Computational docking model of HIV-Tat with SPMG-derived fragments. Predicted interactions between HIV-Tat and SPMG-derived fragments, including di- (A, B, and C), tetra- (D), and octa-saccharide (E) are indicated. Tat is represented by a surface and oligosaccharides by stick model. The Tat surface is colored by electrostatic potential in A. In C-E, it is wheat-colored, with the KKR region and basic domain highlighted in yellow and green, respectively. A close-up view of the binding interface between the di-saccharide and the KKR (Lys12, Lys41, and Arg78) region is shown in B, where Tat is shown in mesh form and the protein main chain is shown in cartoon style.

Modeling of interactions with tetra- and octa-saccharides revealed similar results; the positively charged KKR triad plays an important role in the molecular recognition of SPMG probes by producing a highly conserved interaction with Tat-III. It should be noted that the oligosaccharide chain begins to stretch toward the basic domain (green for comparison, Figure 1D and 1E) as the probe length increases. As the length increases to a tetramer, a delicate interaction with residue Arg56 of the basic domain is established. The octamer follows the same path and approaches residue Arg53 (Figure 1D and 1E). Ideally, SPMG, if long enough, is proposed to fully extend to encompass both the KKR region and the whole basic domain.

The KKR domain is spatially enclosed to bind to SPMG

To characterize the Tat KKR triad engagement with SPMG, a series of Tat mutants were expressed in E coli as GST-Tat fusion proteins, purified from bacterial lysates by glutathione-agarose affinity chromatography, and checked by SDS-PAGE.

First, the EC50 binding capacity was evaluated. For this evaluation, a series of GST-Tat solutions with a range of concentrations (0.25, 0.5, 1, 2, or 4 μmol/L) were injected over an SPMG-immobilized sensor chip surface. RUmax values were generated using BIAcore evaluation 3.1 software, yielding an EC50 value of 1.5 μmol/L (data not shown); this value was used as a reference for subsequent experiments.

We next investigated whether KKR was an SPMG binding site, as predicted. A series of comparative studies were performed using all relevant mutants. We found that GST-Tat binding to SPMG exhibited a multi-phasic binding profile (Figure 2A), indicating the existence of more than one SPMG binding site. Notably, mutation of the basic domain still produced monophasic binding, further supporting the notion that a binding site for SPMG exists in addition to the basic domain (Figure 2B). Accordingly, the mutation of Lys12, Lys41, and Arg78 to alanine [GST-TatK (12,41)A/R78A] displayed a markedly decreased binding potency for SPMG when compared to wild-type GST-Tat (Figure 2C). Moreover, double-mutant GST-Tat(G48-R57)A/K(12,41)A/R78A led to complete abolishment of Tat-SPMG interactions (Figure 2C). These findings substantiate our hypothesis that Tat possesses another SPMG binding site, the KKR region.

Figure 2.

Figure 2

Open in a new tab

Identification of the Tat Lys12, Lys41, Arg78 (KKR) domain as a new SPMG binding site. (A, B) Scatchard plot analysis of GST-Tat (A) and GST-Tat(G48-R57)A (B) with immobilized SPMG. A series of concentrations of GST-Tat or GST-Tat(G48-R57)A were injected over the SPMG-immobilized sensor chip surface. The binding potency/concentration (RU/C) was plotted versus RU. (C) Interaction of GST-Tat and its mutants with biotinylated SPMG immobilized on a CM5 sensor chip. GST-Tat or the appropriate mutants (1.5 μmol/L) were injected over the SPMG-immobilized sensor chip. The binding RU was recorded as binding potency.

We next clarified the contribution of the three basic residues as a whole and separately. Single, double, and triple mutations of the KKR region were constructed and their binding affinities (KD) for immobilized SPMG were recorded and compared. KD values were calculated using BIAcore evaluation 3.1 software. Mutation of a single residue (GST-TatK12A, GST-TatK41A, or GST-TatR78A) led to only a partial loss of SPMG binding affinity (KD 0.112 nmol/L, 0.174 nmol/L, or 0.0729 nmol/L, respectively), with the Arg78 mutation (GST-TatR78A) influencing binding affinity the least (Table 2). Mutation of any two KKR residues (GST-TatK(12,41)A, GST-TatK12A/R78A, or GST-TatK41A/R78A) led to a significant loss of binding affinity with correspondingly decreased KD values (1.04 nmol/L, 0.435 nmol/L and 0.205 nmol/L, respectively), with the Lys12, Lys41 mutation (GST-TatK(12,41)A) affecting binding the most (Table 2). Most significantly, concurrent mutation of all three residues produced a dramatic drop in SPMG binding affinity, with a resultant KD value of 11 nmol/L (Table 2). These findings collectively indicated that Lys12, Lys41 and Arg78 cooperated as a whole to profoundly impact SPMG binding.

Table 2. The affinity parameters for binding of GST-Tat and its mutants to SPMG.

Analyte KA [1/(mol·L−1)] KD (mol/L)
GST-Tat 4.13×1010 2.42×10−11
GST-Tat(G48-R57)A 3.77×1010 2.65×10−11
GST-TatK(12, 41)A/R78A 9.08×107 1.10×10−8
GST-TatK12A 8.93×109 1.12×10−10
GST- TatK41A 5.73×109 1.74×10−10
GST- TatR78A 1.37×1010 7.29×10−11
GST- TatK(12, 41)A 9.65×108 1.04×10−9
GST-TatK12A/R78A 2.30×109 4.35×10−10
GST- TatK41A/R78A 4.88×109 2.05×10−10
Open in a new tab

KA: equilibrium association constant; KD: equilibrium dissociation constant. Data shown are representative of three independent experiments with similar results.

The KKR triad binds specifically to SPMG in a high affinity manner

We next sought to delineate the nature of the interaction between KKR and SPMG. We first assessed binding affinity. Various concentrations of GST-Tat, GST-Tat(G48-R57)A, and GST-TatK(12,41)A/R78A were injected over an SPMG-immobilized sensor chip surface (Figure 3A–3C). We found that GST-Tat bound to SPMG (KD=24.2 pmol/L) (Table 2). Mutation of the basic domain (leaving the KKR domain intact and thus solely responsible for the strength of the Tat KKR-SPMG interaction) had little effect on binding affinity (KD=26.5 pmol/L). Notably, mutation of the KKR region caused a remarkable decrease in GST-Tat-SPMG binding (KD=11 nmol/L), representing the KD value of the basic domain in isolation. This KD represents a 500 fold decrease in binding affinity compared with that of wild-type GST-Tat (Table 2). Based on this comparison, we conclude that the KKR spatial region dominates Tat-SPMG binding compared to the basic domain.

Figure 3.

Figure 3

Open in a new tab

Characterization of the intrinsic properties of the Tat KKR SPMG binding domain. (A-C) Sensorgrams of GST-Tat and its mutants with immobilized SPMG. Serial concentrations of GST-Tat and its mutants were injected over the SPMG-immobilized sensor chip surface. The real time binding was recorded as response (RU) versus time. (A), (B) and (C) represent sensorgrams for GST-Tat, GST-Tat(G48-R57)A, and GST-TatK(12,41)A/R78A, respectively.

For further confirmation, we conducted a series of competitive inhibition assays. Wild-type GST-Tat or the appropriate Tat mutants (1.5 μmol/L) were injected over an SPMG-immobilized chip in the presence of varying concentrations of SPMG as a competitive inhibitor. Free SPMG was able to inhibit the binding of either GST-Tat or the corresponding mutant to immobilized SPMG in a dose-dependent manner (Figure 4A–4C). Notably, mutation of the basic domain (GST-Tat(G48-R57)A) produced an IC50 value (1.803 μg/mL) comparable to that of GST-Tat (1.808 μg/mL), while mutation of the KKR region (GST-TatK(12,41)A/R78A) yielded an IC50 value of 3.259 μg/mL, almost twice that of GST-Tat. These data further support the notion that the KKR spatial domain contributes dramatically to SPMG binding and represents an extremely high-affinity SPMG binding site.

Figure 4.

Figure 4

Open in a new tab

SPMG competitively inhibits binding of GST-Tat and its mutants with immobilized SPMG. GST-Tat (A), GST-Tat(G48-R57)A (B) and GST-TatK(12,41)A/R78A (C) (1.5 μmol/L) alone or in the presence of serial concentrations of SPMG were injected over an SPMG immobilized chip surface. The responses (in RU) were plotted versus the concentration of SPMG. Insets show the overlay of sensorgrams showing the binding of GST-Tat and its mutants to immobilized SPMG in the presence of increasing concentrations of SPMG. (D) The inhibitory action of different glycosaminoglycans on GST-Tat(G48-R57)A-SPMG interaction. GST-Tat(G48-R57)A (1.5 μmol/L) was preincubated with the indicated concentrations of free heparin, heparan sulfate (HS), chondroitin sulfates A (CSA), C (CSC), or hyaluronic acid (HA) and injected over a biotinylated SPMG surface.

We then characterized KKR binding specificity via the introduction of soluble glycosaminoglycans (GAGs). Both heparin and HS were able to compete for KKR binding to SPMG, yielding IC50 values of 0.633 μg/mL and 41.314 μg/mL, respectively. By contrast, other GAGs including CSA, CSC, and HA, even at concentrations up to 125 μg/mL, showed little or no inhibition of this interaction (Figure 4D). These findings suggest the binding specificity of the KKR region for SPMG is high.

Collectively, these data support the hypothesis that the KKR region of Tat, distinct from the well-recognized linearly contiguous basic domain, serves as a binding motif for SPMG that has extremely high affinity and is highly specific.

SPMG inhibits KKR-facilitated Tat-mediated SLK cell adhesion.

Because the KKR region facilitates Tat-mediated SLK cell adhesion in a cell surface HSPG-dependent manner14, we then examined the effects of SPMG on SLK cell adhesion. We found that both Tat and KKR-dominant Tat (GST-Tat(G48-R57)A) significantly induced the adhesion of SLK cells, although the KKR-dominant Tat induced cell adhesion to a lower extent. Notably, 200 μg/mL of SPMG dramatically inhibited SLK adhesion (Figure 5). Together, these findings clearly support the idea that SPMG inhibits KKR region-facilitated SLK cell adhesion by directly binding to the KKR region.

Figure 5.

Figure 5

Open in a new tab

Inhibitory effects of SPMG on Tat-mediated SLK cell adhesion (n=3). cP<0.01 vs GST; fP<0.01 vs GST-Tat or GST-Tat(G48-R57)A.

Discussion

In the present study, we demonstrated that the triad of Lys12, Lys41, and Arg78 functioned as a crucial determinant of Tat-SPMG interaction in addition to the basic domain.

Using an SPR assay, a multiphasic binding mode between Tat and SPMG was observed. With mutation of the basic domain, a monophasic binding series became evident. A complete loss of binding capacity for SPMG was then noted following double mutation of both KKR and the basic domain. These findings collectively support the idea that the Tat protein offers two binding sites for SPMG. One is the well-recognized basic domain, and the other is the newly identified KKR region. This model is congruent with our simulation-based predictions. Notably, the mutants with either a single or a double substitution of KKR residues did not dramatically affect SPMG binding affinity, while a triple mutation significantly did. This finding highlights the importance of all three residues in this triad for functionality.

By kinetic analysis, the dissociation constant (KD value) was calculated as 26.5 pmol/L, which represents an extremely high-affinity binding interaction (about 500 times that of the basic domain). The disparity in binding affinity between the KKR and the basic domain, in principle, should allow SPMG to preferentially occupy KKR. In silico simulation clearly demonstrated that SPMG could specifically recognize the KKR region when the disaccharide probe was used. As the length of the oligosaccharide increased, the oligomer stretched toward and along the basic domain; it began to form interactions with Arg56 when the tetramer probe was used and reached Arg53 as the sugar length increased to 8. Ideally, SPMG at its typical length would simultaneously bind to both KKR and the whole basic domain.

An interesting feature of the KKR domain is its specificity for SPMG, as evident from the observation that only heparin/HS but not other GAGs, including CSA, CSC and HA, were able to produce a dose-response-based competitive inhibitory effect on Tat-SPMG interactions. Sugar-protein interactions are predominantly dependent on saccharide composition and the extent and distribution of sulfation of the sugar backbone25, 26. SPMG is a heparin-like sulfated polysaccharide and is rich in 1, 4-linked β-D-mannuronate. The high affinity of Tat for SPMG might be the outcome of both its defined sulfate groups and its specific saccharide composition. In addition, unlike the linearly contiguous sequence of the basic domain, the KKR residues of the novel SPMG binding site, although distant in sequence, are brought into close spatial proximity via Tat conformational folding. This finding is highly consistent with current views, which hold that heparin binding sites are commonly recognized on the external surface of proteins and correspond to shallow pockets of positive charge that are often linearly contiguous or, alternatively, may be distant in sequence yet closely spatially orientated when the protein assumes its native tertiary structure27, 28, 29.

The KKR region facilitates Tat-mediated SLK cell adhesion in a cell surface HSPG-dependent manner14. In the present study, we found that SPMG dramatically inhibited SLK adhesion induced by Tat and KKR-dominant Tat (GST-Tat(G48-R57)A) as well, suggesting the interaction of SPMG with the KKR region competitively abrogated Tat-mediated cell adhesion.

In sum, we herein show that a domain consisting of a triad of Lys12, Lys41, and Arg78 is a novel, high-affinity, spatially enclosed SPMG binding site on Tat. This finding, together with the fact that SPMG inhibits Tat-induced AIDS-KS, provides important new insights into the molecular mechanism of SPMG and a potential therapeutic intervention for Tat-related Kaposi's sarcoma.

Author contribution

Han-dong JIANG and Xin-liang XIN conceived and designed the experiments. Yan-lin WU, Jing AI, Xin-liang XIN, Jing-ming ZHAO, and Xiao-jie XIN performed the experiments. Yan-lin WU, Jing AI, Mei-yu GENG, Han-dong JIANG, and Xin-liang XIN analyzed the data. Han-dong JIANG and Jing AI wrote the paper. And Bing XIONG designed and executed molecular docking.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No 30772884).

References

  1. Dezube BJ. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment. Expert Rev Anticancer Ther. 2002;2:193–200. doi: 10.1586/14737140.2.2.193. [DOI] [PubMed] [Google Scholar]
  2. Aversa SM, Cattelan AM, Salvagno L, Crivellari G, Banna G, Trevenzoli M, et al. Treatments of AIDS-related Kaposi's sarcoma. Crit Rev Oncol Hematol. 2005;53:253–65. doi: 10.1016/j.critrevonc.2004.10.009. [DOI] [PubMed] [Google Scholar]
  3. Sullivan RJ, Pantanowitz L, Dezube BJ. Targeted therapy for Kaposi sarcoma. BioDrugs. 2009;23:69–75. doi: 10.2165/00063030-200923020-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood. 2004;104:810–4. doi: 10.1182/blood-2003-07-2533. [DOI] [PubMed] [Google Scholar]
  5. Pati S, Foulke JS Jr, Barabitskaya O, Kim J, Nair BC, Hone D, et al. Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat. J Virol. 2003;77:5759–73. doi: 10.1128/JVI.77.10.5759-5773.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood. 1999;94:663–72. [PubMed] [Google Scholar]
  7. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis. 2002;5:141–51. doi: 10.1023/a:1023892223074. [DOI] [PubMed] [Google Scholar]
  8. Ziegler A, Seelig J. Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys J. 2004;86:254–63. doi: 10.1016/S0006-3495(04)74101-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D, et al. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem. 1997;272:11313–20. doi: 10.1074/jbc.272.17.11313. [DOI] [PubMed] [Google Scholar]
  10. Rusnati M, Tulipano G, Spillmann D, Tanghetti E, Oreste P, Zoppetti G, et al. Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J Biol Chem. 1999;274:28198–205. doi: 10.1074/jbc.274.40.28198. [DOI] [PubMed] [Google Scholar]
  11. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, Giacca M, et al. The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J Biol Chem. 1998;273:16027–37. doi: 10.1074/jbc.273.26.16027. [DOI] [PubMed] [Google Scholar]
  12. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem. 2001;276:3254–61. doi: 10.1074/jbc.M006701200. [DOI] [PubMed] [Google Scholar]
  13. Fittipaldi A, Giacca M. Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev. 2005;57:597–608. doi: 10.1016/j.addr.2004.10.011. [DOI] [PubMed] [Google Scholar]
  14. Ai J, Xin X, Zheng M, Wang S, Peng S, Li J, et al. A triad of Lys12, Lys41, Arg78 spatial domain, a novel identified heparin binding site on Tat protein, facilitates Tat-driven cell adhesion. PLoS One. 2008;3:e2662. doi: 10.1371/journal.pone.0002662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rusnati M, Urbinati C, Caputo A, Possati L, Lortat-Jacob H, Giacca M, et al. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J Biol Chem. 2001;276:22420–5. doi: 10.1074/jbc.M010779200. [DOI] [PubMed] [Google Scholar]
  16. Hui B, Xia W, Li J, Wang L, Ai J, Geng M. Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, blocks neuroinflammatory signalling by targeting the transactivator of transcription (Tat) protein. J Neurochem. 2006;97:334–44. doi: 10.1111/j.1471-4159.2006.03698.x. [DOI] [PubMed] [Google Scholar]
  17. Lu CX, Li J, Sun YX, Qi X, Wang QJ, Xin XL, et al. Sulfated polymannuroguluronate, a novel anti-AIDS drug candidate, inhibits HIV-1 Tat-induced angiogenesis in Kaposi's sarcoma cells. Biochem Pharmacol. 2007;74:1330–9. doi: 10.1016/j.bcp.2007.06.012. [DOI] [PubMed] [Google Scholar]
  18. Peloponese JM Jr, Gregoire C, Opi S, Esquieu D, Sturgis J, Lebrun E, et al. 1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C R Acad Sci III. 2000;323:883–94. doi: 10.1016/s0764-4469(00)01228-2. [DOI] [PubMed] [Google Scholar]
  19. Sali A. Comparative protein modeling by satisfaction of spatial restraints. Mol Med Today. 1995;1:270–7. doi: 10.1016/s1357-4310(95)91170-7. [DOI] [PubMed] [Google Scholar]
  20. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61. doi: 10.1002/jcc.21334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. DeLano WL.The PyMOL Molecular Graphics System 2002. Available from: : http://www.pymol.org .
  22. Li FC, Qi X, Geng MY. A novel method of Immobilization of 911 for surface plasmon resonance biosensor. Chin J Anal Chem. 2003;31:266–9. [Google Scholar]
  23. Liu H, Geng M, Xin X, Li F, Zhang Z, Li J, et al. Multiple and multivalent interactions of novel anti-AIDS drug candidates, sulfated polymannuronate (SPMG)-derived oligosaccharides, with gp120 and their anti-HIV activities. Glycobiology. 2005;15:501–10. doi: 10.1093/glycob/cwi031. [DOI] [PubMed] [Google Scholar]
  24. Hutchings H, Ortega N, Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J. 2003;17:1520–2. doi: 10.1096/fj.02-0691fje. [DOI] [PubMed] [Google Scholar]
  25. Mulloy B. The specificity of interactions between proteins and sulfated polysaccharides. An Acad Bras Cienc. 2005;77:651–64. doi: 10.1590/s0001-37652005000400007. [DOI] [PubMed] [Google Scholar]
  26. Katsuraya K, Nakashima H, Yamamoto N, Uryu T. Synthesis of sulfated oligosaccharide glycosides having high anti-HIV activity and the relationship between activity and chemical structure. Carbohydr Res. 1999;315:234–42. doi: 10.1016/s0008-6215(98)00315-2. [DOI] [PubMed] [Google Scholar]
  27. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002;41:391–412. doi: 10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  28. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays. 1998;20:156–67. doi: 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  29. Munoz EM, Linhardt RJ. Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol. 2004;24:1549–57. doi: 10.1161/01.ATV.0000137189.22999.3f. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Acta Pharmacologica Sinica are provided here courtesy of Nature Publishing Group

RESOURCES